ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 941,64
0,00%
Dow Jones
44 882,13
0,38%
DAX
21 727,20
0,48%
Brent Oil
76,275
0,30%
Bitcoin
104 426,47
-0,29%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ

  6. Mesoblast Limited (MESO) Cours

Mesoblast Limited

Mesoblast Limited (MESO)

NASDAQ
19,52
-0,03
(-0,15%)
Fermé 31 Janvier 10:00PM
Retardé de 15 minutes
19,20
-0,32
(-1,64%)
Après les heures de négociation: 1:50AM
Retardé de 15 minutes

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Statistiques et détails clés

Dernier
19,20
Prix Achat
18,95
Prix Vente
19,79
Volume échangé
295 587
19,20 Fourchette du Jour 20,20
0,00 Plage de 52 semaines 0,00
Cap du marché
2,192B
Clôture Veille
19,55
Ouverture
19,20
Dernière Transaction
100
@
19.2
(formt)
Dernière heure de transaction
Volume financier
US$ 5 830 221
VWAP
19,7242
Volume moyen (3 m)
-
Actions en circulation
114 178 411
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-4,08
Bénéfice par action (BPA)
-0,77
Chiffre d'affairess
9,25M
Bénéfice net
-87,96M

À propos de Mesoblast Limited

Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-... Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) and others. Show more

Secteur
Biological Pds,ex Diagnstics
Industrie
Biological Pds,ex Diagnstics
Site Web
www.mesoblast.com
Siège social
Melbourne, Victoria, Aus
Fondé
-
Mesoblast Limited est coté dans le secteur Biological Pds,ex Diagnstics de la NASDAQ avec le ticker MESO. Le dernier cours de clôture d'Mesoblast était de US$19,55. Au cours de la dernière année, les actions de Mesoblast ont été négociées dans une fourchette de prix de US$ 0,00 à US$ 0,00.

Mesoblast compte actuellement 114 178 411 actions en circulation. La capitalisation boursière d'Mesoblast est de US$2,23 milliard. Mesoblast a un ratio cours/bénéfice (ratio PE) de -4.08.

MESO Dernières nouvelles

Plus de nouvelles

Ryoncil® Commercial Launch Update and Product Pipeline

NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on the...

il y a 6 heures
GlobeNewswire Inc.

Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2024

NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its...

il y a 7 heures
GlobeNewswire Inc.

Mesoblast’s RYONCIL® is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy

RYONCIL (remestemcel-L) is the first MSC product approved by FDA for any indication.RYONCIL is the first FDA-approved therapy for children aged 2 months and older, including adolescents and...

19 Décembre 2024
GlobeNewswire Inc.

Mesoblast to be Added to Nasdaq Biotechnology Index

NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced its upcoming...

18 Décembre 2024
GlobeNewswire Inc.

Form F-3 - Registration statement by foreign private issuers

13 Décembre 2024
Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

09 Décembre 2024
Edgar (US Regulatory)

FDA Grants Revascor® (Rexlemestrocel-L) Regenerative Medicine Advanced Therapy (RMAT) Designation in Children with Congenital Heart Disease

NEW YORK, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the United States...

05 Décembre 2024
GlobeNewswire Inc.

Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With Inflammation

NEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced a key publication...

03 Décembre 2024
GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

18 Novembre 2024
Edgar (US Regulatory)

Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2024

NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its...

31 Octobre 2024
GlobeNewswire Inc.
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

MESO - Frequently Asked Questions (FAQ)

What is the current Mesoblast share price?
The current share price of Mesoblast is US$ 19,20
How many Mesoblast shares are in issue?
Mesoblast has 114 178 411 shares in issue
What is the market cap of Mesoblast?
The market capitalisation of Mesoblast is USD 2,23B
What is the 1 year trading range for Mesoblast share price?
Mesoblast has traded in the range of US$ 0,00 to US$ 0,00 during the past year
What is the PE ratio of Mesoblast?
The price to earnings ratio of Mesoblast is -4,08
What is the cash to sales ratio of Mesoblast?
The cash to sales ratio of Mesoblast is 38,77
What is the reporting currency for Mesoblast?
Mesoblast reports financial results in USD
What is the latest annual turnover for Mesoblast?
The latest annual turnover of Mesoblast is USD 9,25M
What is the latest annual profit for Mesoblast?
The latest annual profit of Mesoblast is USD -87,96M
What is the registered address of Mesoblast?
The registered address for Mesoblast is LEVEL 38, 55 COLLINS STREET, MELBOURNE, VICTORIA, 3000
What is the Mesoblast website address?
The website address for Mesoblast is www.mesoblast.com
Which industry sector does Mesoblast operate in?
Mesoblast operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
FOXXFoxx Development Holdings Inc
US$ 6,355
(119,90%)
33,52M
BHILBenson Hill Inc
US$ 3,925
(118,06%)
13,52M
TECXTectonic Therapeutic Inc
US$ 55,18
(114,54%)
5,46M
AMODAlpha Modus Holdings Inc
US$ 3,2299
(109,73%)
125,47M
DOMHDominari Holdings Inc
US$ 3,61
(59,03%)
4,24M
CLEUChina Liberal Education Holdings Ltd
US$ 0,149
(-98,08%)
311,38M
CRGXCARGO Therapeutics Inc
US$ 3,39
(-74,30%)
21,21M
TDTHTrident Digital Tech Holdings Ltd
US$ 1,0159
(-58,87%)
2,46M
EVTVEnvirotech Vehicles Inc
US$ 0,338202
(-49,30%)
4,78M
IRWDIronwood Pharmaceuticals Inc
US$ 2,29
(-38,44%)
10,53M
NVDANVIDIA Corporation
US$ 124,65
(0,77%)
392,11M
CLEUChina Liberal Education Holdings Ltd
US$ 0,149
(-98,08%)
311,38M
MGOLMGO Global Inc
US$ 0,1199
(17,90%)
166,88M
SPGCSacks Parente Golf Inc
US$ 0,93
(57,63%)
129,08M
RIMEAlgorhythm Holdings Inc
US$ 0,02465
(-5,19%)
126,09M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

NASDAQ
MESO
Mesoblast
NYSE
WTRG
Essential Utilities
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés

Supprimer les publicités

Inscrivez-vous pour une expérience sans publicité

Aucune publicité

Essayez maintenant

Conserver les annonces